Chikungunya Fever – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Chikungunya Fever – Pipeline Review, H2 2017’, provides an overview of the Chikungunya Fever pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chikungunya Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chikungunya Fever and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Chikungunya Fever

The report reviews pipeline therapeutics for Chikungunya Fever by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chikungunya Fever therapeutics and enlists all their major and minor projects

The report assesses Chikungunya Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Chikungunya Fever

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chikungunya Fever

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chikungunya Fever pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abivax SA

Arno Therapeutics Inc

Bharat Biotech International Ltd

Ennaid Therapeutics LLC

Etubics Corp

Hawaii Biotech Inc

Indian Immunologicals Ltd

Inovio Pharmaceuticals Inc

Integral Molecular Inc

Integrated BioTherapeutics Inc

Moderna Therapeutics Inc

Mymetics Corp

Nanotherapeutics Inc

Paradigm Biopharmaceuticals Ltd

PaxVax Inc

Profectus BioSciences Inc

Shionogi & Co Ltd

Takeda Pharmaceutical Co Ltd

Themis Bioscience GmbH

Valneva SE

Vaxart Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 7

Global Markets Direct Report Coverage 7

Chikungunya Fever - Overview 8

Chikungunya Fever - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 16

Chikungunya Fever - Therapeutics Assessment 17

Assessment by Target 17

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Chikungunya Fever - Companies Involved in Therapeutics Development 25

Abivax SA 25

Arno Therapeutics Inc 25

Bharat Biotech International Ltd 25

Ennaid Therapeutics LLC 26

Etubics Corp 26

Hawaii Biotech Inc 27

Indian Immunologicals Ltd 27

Inovio Pharmaceuticals Inc 27

Integral Molecular Inc 28

Integrated BioTherapeutics Inc 28

Moderna Therapeutics Inc 28

Mymetics Corp 29

Nanotherapeutics Inc 29

Paradigm Biopharmaceuticals Ltd 30

PaxVax Inc 30

Profectus BioSciences Inc 30

Shionogi & Co Ltd 31

Takeda Pharmaceutical Co Ltd 31

Themis Bioscience GmbH 32

Valneva SE 32

Vaxart Inc 33

Chikungunya Fever - Drug Profiles 34

(chikungunya + Zika) (bivalent) vaccine - Drug Profile 34

ABX-311 - Drug Profile 35

AR-12 - Drug Profile 36

BBV-87 - Drug Profile 39

chikungunya (viral like particles) vaccine - Drug Profile 40

chikungunya (virus like particle) vaccine - Drug Profile 41

chikungunya vaccine - Drug Profile 42

chikungunya vaccine - Drug Profile 44

chikungunya vaccine - Drug Profile 45

chikungunya vaccine - Drug Profile 46

chikungunya vaccine - Drug Profile 47

chikungunya vaccine - Drug Profile 48

chikungunya vaccine - Drug Profile 49

chikungunya vaccine - Drug Profile 50

chikungunya vaccine - Drug Profile 51

chikungunya vaccine - Drug Profile 52

chikungunya vaccine - Drug Profile 53

chikungunya vaccine - Drug Profile 54

chikungunya vaccine - Drug Profile 55

chikungunya vaccine - Drug Profile 56

Gene Therapy for Chikungunya - Drug Profile 57

HSRx-431 - Drug Profile 58

IMCKV-063 - Drug Profile 59

Monoclonal Antibodies for Chikungunya - Drug Profile 60

Monoclonal Antibodies for Equine Encephalitis and Chikungunya - Drug Profile 61

Monoclonal Antibodies to Inhibit CHIKV E2 for Chikungunya - Drug Profile 62

mRNA-1388 - Drug Profile 63

MV-CHIK - Drug Profile 64

pentosan polysulfate sodium - Drug Profile 67

Peptides for Infectious Diseases - Drug Profile 71

SCV-305 - Drug Profile 72

Small Molecule to Inhibit NS2 and NS3 for Chikungunya - Drug Profile 73

Small Molecule to Inhibit NS4 for Chikungunya Fever - Drug Profile 74

Small Molecules for Chikungunya - Drug Profile 75

Small Molecules for Chikungunya - Drug Profile 76

Small Molecules for Chikungunya Fever - Drug Profile 77

Small Molecules for Chikungunya Fever - Drug Profile 78

Small Molecules for Infectious Disease - Drug Profile 79

SVIR-001 - Drug Profile 80

Synthetic Peptides for Chikungunya - Drug Profile 81

TAK-507 - Drug Profile 82

Tatbeclin-1 - Drug Profile 83

VLA-1553 - Drug Profile 84

Chikungunya Fever - Dormant Projects 85

Chikungunya Fever - Product Development Milestones 86

Featured News & Press Releases 86

Appendix 99

Methodology 99

Coverage 99

Secondary Research 99

Primary Research 99

Expert Panel Validation 99

Contact Us 99

Disclaimer 100

List of Tables

List of Tables

Number of Products under Development for Chikungunya Fever, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Chikungunya Fever – Pipeline by Abivax SA, H2 2017

Chikungunya Fever – Pipeline by Arno Therapeutics Inc, H2 2017

Chikungunya Fever – Pipeline by Bharat Biotech International Ltd, H2 2017

Chikungunya Fever – Pipeline by Ennaid Therapeutics LLC, H2 2017

Chikungunya Fever – Pipeline by Etubics Corp, H2 2017

Chikungunya Fever – Pipeline by Hawaii Biotech Inc, H2 2017

Chikungunya Fever – Pipeline by Indian Immunologicals Ltd, H2 2017

Chikungunya Fever – Pipeline by Inovio Pharmaceuticals Inc, H2 2017

Chikungunya Fever – Pipeline by Integral Molecular Inc, H2 2017

Chikungunya Fever – Pipeline by Integrated BioTherapeutics Inc, H2 2017

Chikungunya Fever – Pipeline by Moderna Therapeutics Inc, H2 2017

Chikungunya Fever – Pipeline by Mymetics Corp, H2 2017

Chikungunya Fever – Pipeline by Nanotherapeutics Inc, H2 2017

Chikungunya Fever – Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2017

Chikungunya Fever – Pipeline by PaxVax Inc, H2 2017

Chikungunya Fever – Pipeline by Profectus BioSciences Inc, H2 2017

Chikungunya Fever – Pipeline by Shionogi & Co Ltd, H2 2017

Chikungunya Fever – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017

Chikungunya Fever – Pipeline by Themis Bioscience GmbH, H2 2017

Chikungunya Fever – Pipeline by Valneva SE, H2 2017

Chikungunya Fever – Pipeline by Vaxart Inc, H2 2017

Chikungunya Fever – Dormant Projects, H2 2017

List of Figures

List of Figures

Number of Products under Development for Chikungunya Fever, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports